Investor Overview

Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company‚Äôs lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease.  

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

ONVO 3mo Stock Chart
ONVO 6mo Stock Chart
ONVO 1yr Stock Chart
© 2024 Organovo Holdings, Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121